Chemours (NYSE:CC) Stock Bumped Down to Strong Sell by Zacks Research

Zacks Research cut shares of Chemours (NYSE:CC) from a hold rating to a strong sell rating in a research note released on Wednesday morning,Zacks reports.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemours in a research report on Tuesday. BMO Capital Markets reduced their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Truist Financial reduced their price objective on Chemours from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday. Barclays started coverage on shares of Chemours in a research note on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price objective on the stock. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $16.00 target price on shares of Chemours in a research report on Friday, October 9th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $17.45.

Chemours Trading Down 7.4%

Chemours stock opened at $12.77 on Wednesday. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.88 and a current ratio of 1.81. The business’s 50-day simple moving average is $14.02 and its 200-day simple moving average is $18.23. The firm has a market capitalization of $1.92 billion, a PE ratio of -12.51 and a beta of 1.47. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67.

Chemours (NYSE:CC) last announced its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05). The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. Chemours’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.40 EPS. Equities research analysts forecast that Chemours will post 0.81 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a yield of 2.7%. Chemours’s dividend payout ratio (DPR) is -34.31%.

Insider Activity

In other news, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was purchased at an average price of $14.95 per share, with a total value of $50,501.10. Following the acquisition, the chief executive officer directly owned 339,916 shares in the company, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the acquisition, the insider owned 58,547 shares in the company, valued at approximately $909,234.91. This represents a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Chemours during the 2nd quarter worth approximately $477,769,000. Wolf Hill Capital Management LP acquired a new stake in Chemours in the 2nd quarter valued at $59,698,056. Jefferies Financial Group Inc. boosted its stake in Chemours by 251.8% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock valued at $37,210,000 after buying an additional 1,962,523 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Chemours in the 2nd quarter valued at $33,353,000. Finally, Legal & General Group Plc bought a new stake in Chemours in the second quarter valued at $28,400,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.